Free shipping on all orders over $ 500

Enfortumab (anti-Nectin-4)

Cat. No. M21436
Enfortumab (anti-Nectin-4)  Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Enfortumab anti-Nectin-4 is a monoclonal antibody targeting Nectin-4 that acts as an ADC to initiate the internalization of the ADc-Nectin-4 complex and the hydrolyzed cleavage of Monomethylaustatin E (MMAE), The microtubule network was damaged to induce apoptosis. Enfortumab anti-Nectin-4 can be used to study urothelial cancer.

Chemical Information
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Olivier Cabaud, et al. Mol Cancer Ther. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate

[2] Wafa Bouleftour, et al. Mol Cancer Ther. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review

[3] Elisabeth I Heath, et al. Nat Rev Urol. The biology and rationale of targeting nectin-4 in urothelial carcinoma

[4] Zachery Halford, et al. Ann Pharmacother. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma

[5] Pia M Challita-Eid, et al. Cancer Res. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Related Apoptosis Products

Misetionamide is an orally glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with antineoplastic activity.


FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).

Citatuzumab bogatox

Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models.


Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.


Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.

Abmole Inhibitor Catalog

Keywords: Enfortumab (anti-Nectin-4) supplier, Apoptosis, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.